Who Should Not Use Sermorelin Like any growth hormone-stimulating therapy, Sermorelin is contraindicated in patients with active malignancy or a personal history of certain cancers, because anything that drives GH/IGF-1 production has theoretical risk in those settings
In DECLARE-TIMI58 with dapagliflozin, 4.4% of the patients were using GLP-1RAs at baseline, and dapagliflozin reduced the risks of MACE, HHF, and composite kidney outcomes regardless of baseline GLP-1RA use [49]
Study of MDA-LDL by pioglitazone and pitavastatin in patients with type 2 diabetes
Free radicals are found ubiquitously in our bodies thanks to the many environmental pollutants, toxins, processed foods, illnesses and daily stressors that we are surrounded by
Aug 2022;73(1):e12801
(34221552) Other mechanisms might include reduced calcium entry into neurons and enhanced GABA activity